TICKERNERD
Menu
CBIOCBIOHealthcare · Biotechnology

CBIO Stock Forecast: Crescent Biopharma, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$13
−4.19% on the day

The 8 Wall Street analysts covering Crescent Biopharma, Inc. hold a median 12-month price target of $32 — +133.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$500.7M
Ticker Nerd rank
46/ 100
Median analyst target
$32
Analysts covering
8
Revenue$0.0
Operating income−$26.4M
Net income−$24.8M
Free cash flow−$19.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.1%
1M
−7.6%
YTD
+13.7%
1Y
+7.8%
From 52W high
−50.0%
From 52W low
+50.8%
$9
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Crescent Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
46/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
79
Volatility
61
Momentum
61
Accruals
55
Size
52
Quality
47
Growth
41
Revisions
37
Issuance
28

Value (79): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26CBIOHigh $36Median $32Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $27Median $32High $36

The green dot is the last close — the median target sits +133.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Oct 2026HC Wainwright & Co.ReiteratesBuy$36
6 Oct 2026HC Wainwright & Co.UpgradeBuy$36
6 Oct 2026HC Wainwright & Co.UpgradeBuy—
14 Sept 2026WedbushReiteratesOutperform$27
14 Sept 2026WedbushReiteratesOutperform—
27 Aug 2026WedbushReiteratesOutperform$27
27 Aug 2026WedbushReiteratesOutperform—
1 June 2026HC Wainwright & Co.DowngradeNeutral—
1 June 2026HC Wainwright & Co.DowngradeNeutral—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
21 Jan 2026GuggenheimInitiatesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
25 Aug 2025JefferiesInitiatesBuy—
11 Aug 2025HC Wainwright & Co.InitiatesBuy—
14 July 2025WedbushInitiatesOutperform—
25 June 2025StifelInitiatesBuy—
18 June 2025LifeSci CapitalInitiatesOutperform$22
15 Nov 2021Raymond JamesDowngradeMarket Perform—
6 Aug 2021Raymond JamesMaintainsOutperform$19 → $18
29 Apr 2021Raymond JamesMaintainsOutperform$18 → $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Crescent Biopharma, Inc. returned +7.8% against +12.4% for the S&P 500, dividends included.

CBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26CBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Crescent Biopharma, Inc. (CBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.6×

Cheaper than 69% of US stocks

Price / sales
42.1×

Cheaper than 5% of US stocks

Price / book
2.8×

Cheaper than 32% of US stocks

EV / EBITDA
−2.6×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1432.6%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−75.8%

Higher than 16% of US stocks

Return on assets
−64.1%

Higher than 6% of US stocks

Dividend yield
709.5%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Crescent Biopharma, Inc. (CBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Crescent Biopharma, Inc. has a market value of $500.7M and an enterprise value of $436.1M.

  • Revenue in the twelve months to 30 June 2026: $11.9M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$165.1M, a −1389.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−6.72.

  • Free cash flow in the twelve months to 30 June 2026: −$153.6M.

  • Shares outstanding: 27.8M.

  • Trailing P/E: 2.6×; forward P/E: −5.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 709.53%, paying out 0% of earnings.

  • Crescent Biopharma, Inc. employs 69 people — $172K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

CBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CBIOCrescent Biopharma, Inc.$500.7M46
DMACDiaMedica Therapeutics, Inc.$498.8M56
ARVNArvinas, Inc.$504.8M69
CTMXCytomX Therapeutics, Inc.$505.9M42
GYREGyre Therapeutics, Inc.$507.8M48
ETRAElectra Therapeutics, Inc.$508.4M1
OCSOculis Holding AG$509.9M27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Crescent Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CBIO news & analysis

Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001

GlobeNewsWire · 15 Oct 2026positive

Crescent reported that its global Phase 1/2 ASCEND trial of CR-001 has dosed more than 125 patients, completed dose escalation, and begun enrolling patients in chemotherapy-combination expansion cohorts across several solid tumor types. The company also said additional CR-001 ADC combination studies are advancing and outlined expected data and trial milestones for its pipeline.

Why it matters — The update provides CBIO watchers with progress on enrollment and development timelines for CR-001 and other clinical programs.

Crescent Biopharma Announces Grants of Inducement Awards

GlobeNewsWire · 6 Oct 2026neutral

Crescent Biopharma announced that its independent Compensation Committee approved options to purchase 81,525 ordinary shares for six non-executive employees as inducement awards. The options were approved on October 5, 2026, under the company’s amended 2025 Employment Inducement Incentive Award Plan.

Why it matters — CBIO watchers may note the equity awards as part of the company’s hiring and compensation activity.

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

GlobeNewsWire · 5 Oct 2026neutral

Crescent Biopharma announced that the FDA cleared the company's Investigational New Drug (IND) application for CR-002, a PD-L1-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) intended for the treatment of solid tumors. The Phase 1/2 APOLLO global clinical trial will evaluate CR-002 across multiple solid tumor types, including non-small cell lung cancer and head and neck squamous cell carcinoma, and is on track to begin in the fourth quarter of 2026.

Why it matters — This FDA clearance advances CR-002 into a planned global clinical trial, giving Crescent Biopharma watchers a near-term regulatory and clinical development milestone for one of the company's lead candidates.

Crescent Biopharma Announces Grants of Inducement Awards

GlobeNewsWire · 25 Sept 2026neutral

Crescent Biopharma's Compensation Committee approved the grant of options covering an aggregate of 31,200 ordinary shares to two non-executive employees as equity inducement awards under its 2025 Employment Inducement Incentive Award Plan. The options, approved September 24, 2026, were material to each employee's acceptance of employment and comply with Nasdaq Listing Rule 5635(c)(4).

Why it matters — CBIO watchers would care because the inducement grants signal new hires incentivized under the company's equity plan, a routine corporate governance disclosure for investors to track.

Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

Crescent Biopharma, Inc. (CBIO) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available via Seeking Alpha. The item reports the company's participation in the conference event.

Why it matters — The presentation gives CBIO watchers direct insight into how the company is communicating its business to the investment community at a major industry conference.

FAQ

Frequently asked questions about CBIO stock

What is the CBIO stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Crescent Biopharma, Inc. have a median 12-month price target of $32, with estimates ranging from $27 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CBIO stock a buy right now?

Of the 8 analysts covering Crescent Biopharma, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Crescent Biopharma, Inc. 46 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CBIO?

As at 31 Oct 2026, Crescent Biopharma, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (79 of 100).

Will CBIO stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +133.7% from the last close, and Ticker Nerd's factor model ranks Crescent Biopharma, Inc. 46 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CBIO stock forecast for 2030?

No analyst covering Crescent Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $36 over the next 12 months.

How has CBIO stock performed over the past year?

Crescent Biopharma, Inc. returned +7.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Crescent Biopharma, Inc. do?

Crescent Biopharma Inc. is a clinical-stage biotechnology company focused on developing oncology therapeutics for solid tumors.

What is the latest news on CBIO?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001". Crescent reported that its global Phase 1/2 ASCEND trial of CR-001 has dosed more than 125 patients, completed dose escalation, and begun enrolling patients in chemotherapy-combination expansion cohorts across several solid tumor types. The company also said additional CR-001 ADC combination studies are advancing and outlined expected data and trial milestones for its pipeline.

Company

About Crescent Biopharma, Inc.

Crescent Biopharma Inc. is a clinical-stage biotechnology company focused on developing oncology therapeutics for solid tumors. Its current pipeline centers on antibody-based programs, including bispecific antibodies and antibody-drug conjugates designed to address key biological pathways involved in cancer growth and progression. The company’s lead efforts include CR-001, a PD-1 x VEGF bispecific antibody, along with additional candidates aimed at treating advanced solid tumors. Crescent Biopharma Inc. operates in the highly specialized biopharmaceutical sector, where research, clinical development, and strategic collaborations are central to advancing new treatment options. The company’s role in the market is defined by its emphasis on precision-engineered cancer therapies and its focus on late-stage disease areas with significant unmet medical need.

CEO Mr. Joshua T. Brumm · 69 employees · United States · https://crescentbiopharma.com